Biocon Limited

Four Months After Itolizumab ‘Trial’ and 9 Million Infections Later – No Progress

A Good Registry Means Accountable Clinical Trials. But Does India Have One?

Itolizumab for COVID-19: Who Benefits When the Drug Regulator Is Opaque?

How Effective Are the Drugs Approved to Treat COVID-19 Patients in India?

Is Biocon’s Itolizumab Good News? Hard to Tell, Thanks to the Bad Science.